Rifampicin-Induced Minimal Change Disease Is Improved after Cessation of Rifampicin without Steroid Therapy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
There are several reports to demonstrate that rifampicin, a major anti-tuberculosis agent, is associated with some adverse renal effects, with a few cases of rifampicin-induced minimal change disease (MCD). In the present case, a 68-year-old female presented with nausea, vomiting, foamy urine, general weakness and edema. She had been taking rifampicin for 4 weeks due to pleural tuberculosis. The patient had no proteinuria before the anti-tuberculosis agents were started, but urine tests upon admission showed heavy proteinuria with a 24-h urinary protein of 9.2 g/day, and serum creatinine, albumin, and total cholesterol levels were 1.36 mg/dL, 2.40 g/dL, and 283 mg/dL, respectively. MCD was diagnosed, and the patient achieved completeremission after cessation of rifampicin without undergoing steroid therapy.
Abstract
There are several reports to demonstrate that rifampicin, a major anti-tuberculosis agent, is associated with some adverse renal effects, with a few cases of rifampicin-induced minimal change disease (MCD). In the present case, a 68-year-old female presented with nausea, vomiting, foamy urine, general weakness and edema. She had been taking rifampicin for 4 weeks due to pleural tuberculosis. The patient had no proteinuria before the anti-tuberculosis agents were started, but urine tests upon admission showed heavy proteinuria with a 24-h urinary protein of 9.2 g/day, and serum creatinine, albumin, and total cholesterol levels were 1.36 mg/dL, 2.40 g/dL, and 283 mg/dL, respectively. MCD was diagnosed, and the patient achieved completeremission after cessation of rifampicin without undergoing steroid therapy.
참고문헌 (13)
- Covic A, "Rifampicin-induced acute renal failure: a series of 60 patients", Nephrol Dial Transplant, 13, pp.924~929 (1998)
- De Vriese AS, "Rifampicin-associated acute renal failure: pathophysiologic, immunologic, and clinical features", Am J Kidney Dis, 31, pp.108~115 (1998)
- Gabow PA, "Tubulointerstitial and glomerular nephritis associated with rifampin. Report of a case", JAMA, 235, pp.2517~2518 (1976)
- Kohno K, "Minimal change nephrotic syndrome associated with rifampicin treatment", Nephrol Dial Transplant, 15, pp.1056~1059 (2000)
- Murray AN, "Rapidly progressive glomerulonephritis associated with rifampicin therapy for pulmonary tuberculosis", Nephron, 46, pp.373~376 (1987)
- Muthukumar T, "Acute renal failure due to rifampicin: a study of 25 patients", Am J Kidney Dis, 40, pp.690~696 (2002)
- Neugarten J, "Rifampin-induced nephrotic syndrome and acute interstitial nephritis", Am J Nephrol, 3, pp.38~42 (1983)
- Rekha VV, "Rifampicin-induced renal toxicity during retreatment of patients with pulmonary tuberculosis", J Assoc Physicians India, 53, pp.811~813 (2005)
- Tada T, "A case report of nephrotic syndrome associated with rifampicin therapy", Nihon Jinzo Gakkai Shi, 37, pp.145~150 (1995)
- Yoshioka K, "Rapidly progressive glomerulonephritis due to rifampicin therapy", Nephron, 90, pp.116~118 (2002)
- Black DA, "Controlled trial of prednisone in adult patients with the nephrotic syndrome", Br Med J, 3, pp.421~426 (1970)
- Waldman M, "Adult minimal-change disease: clinical characteristics, treatment, and outcomes", Clin J Am Soc Nephrol, 2, pp.445~453 (2007)
- Glassock RJ., "Secondary minimal change disease", Nephrol Dial Transplant, 18(Suppl 6), pp.vi52~vi58 (2003)